Physician profile
Chloe Kellam
NPI 1477249464
$2,035.90
in general payments reported to CMS, 2019-2025
23 companies · $880 in 2025
The $880 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $288 · 2024: $867 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,942 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,941.90 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $595.41 | 2023-2025 | |
| Astellas Pharma US INC | $306.53 | 2024-2025 | Veozah |
| Novo Nordisk INC | $239.16 | 2023-2025 | Wegovy |
| Biogen, INC. | $192.73 | 2024-2025 | Zurzuvae |
| Organon LLC | $136.04 | 2023-2024 | Nexplanon |
| Abbvie INC. | $72.00 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $55.69 | 2025 | Myfembree, Gemtesa |
| Cepheid | $46.41 | 2025 | Genexpert |
| Lilly USA, LLC | $43.23 | 2025 | Zepbound, Mounjaro |
| Millicent US INC | $38.73 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Exeltis, USA INC. | $35.94 | 2025 | Slynd |
| Mimedx Group, INC. | $35.42 | 2024 | |
| Shield Therapeutics INC | $34.09 | 2023-2024 | |
| Ardelyx, INC. | $31.22 | 2024 | Ibsrela |
| Coopersurgical, INC. | $25.46 | 2024 | Paragard T 380a |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $25.26 | 2025 | Arista |
| Daiichi Sankyo INC. | $22.48 | 2024 | Injectafer |
| Merck Sharp & Dohme LLC | $21.07 | 2024 | Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $16.65 | 2025 | |
| Pfizer INC. | $16.49 | 2025 | |
| Hologic Sales and Service, LLC | $16.10 | 2024 | Acessa Provu System |
| Amgen INC. | $15.54 | 2024 | Prolia, Evenity |
| Currax Pharmaceuticals LLC | $14.25 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chloe Kellam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.